Finance entity
All 1 tracked stories fall under one category: markets. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.7 in the same window. HEMGENIX appears in 1 tracked Finance story from August 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HEMGENIX. Shared-story counts are live from our verified record — not editorial picks.
A slate of upcoming catalysts could drive the next move for uniQure, CareDx, Adaptive Biotechnologies, Enliven Therapeutics, and Amylyx Pharmaceuticals, all of which posted big gains recently. uniQure's Q3 regulatory filing and September four-year data are key events.
HEMGENIX is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
